WASHINGTON – The government’s chief of AIDS research rewrote a safety report on an American-funded drug study to change its conclusions and delete negative information. Later, he ordered the research resumed over the objections of his staff, documents show.

The chief of the National Institutes of Health’s AIDS Division, Dr. Edmund Tramont, took responsibility for both decisions. He cited his four decades of medical experience and argued that Africans in the midst of an AIDS crisis deserved some leniency in meeting U.S. safety standards, according to interviews and documents obtained by The Associated Press.

Dr. Tramont’s staff, including his top deputy, had urged more scrutiny of the Uganda research site to ensure that it overcame record-keeping problems, violations of federal patient safety safe guards, and other issues that forced a 15-month halt to the research into using nevirapine to prevent African babies from getting AIDS from their mothers.

AP reported Monday that NIH knew about the problems in early 2002 but did not tell the White House before President Bush launched a plan that summer to spread nevirapine throughout Africa. Now, officials are concerned that the drug may cause long-term resistance in patients who received it, foreclosing future treatment options.

“I am not convinced that the site is indeed prepared to become active,” Dr. Jonathan Fishbein, an expert NIH hired to improve the agency’s research practices, wrote Dr. Tramont in July 2003.

Dr. Tramont dismissed the safety monitors’ concerns, saying he didn’t believe they fully understood AIDS. “I am convinced that this site is ready to resume given the limitations of doing re search in any resource-poor, underdeveloped country,” Dr. Tramont wrote July 8, 2003,in response to Dr. Fishbein. “I want this restriction lifted ASAP because this site is now the best in Africa run by black Africans and everyone has worked so hard to get it right as evidenced by the fact that their lab is now certified.”

NIH officials acknowledge Dr. Tramont rewrote the report and overruled his staff on the reopening but said he did so because he was more experienced and had an “honest difference of opinion” with his safety experts. They noted he had no financial interest in nevirapine, and that the troubled study began well before he joined NIH in 2001.

Those who raised objections “were part of a large team of which Dr. Tramont was the head, and it is important that the people involved in that team should express their opinion and there should be discussion,” said Dr. H. Clifford Lane, the NIH’s no. 2 infectious-disease specialist and one of Dr. Tramont’s bosses.

“But at the end of the day the final responsibility lies with the head of the team and it is his job to put that together the way he sees it,” Dr. Lane said.

Dr. Lane said an internal NIH review concluded that Dr. Tramont had not engaged in scientific misconduct. Separately, the National Academy of Sciences continues to investigate whether the Uganda research was valid.

NIH believes it helped save hundreds of thousands of African babies by allowing nevirapine to be used in single doses to block the AIDS virus, Dr. Lane said. But he acknowledged that the research was imperfect, and NIH now believes nevirapine should no longer be a first choice for newborn protection – if other options exist – because of the newly discovered resistance problems.